Depomed (DEPO): Favorable Court Ruling, Mostly Expected - Mizuho
- Japan's Nikkei posts biggest point gain for fiscal year
- Citi downgrades tech stocks as its flagship indicator signals 'euphoria' levels
- UBS sees 5 warnings signals on semiconductor chip stocks
- 2 reasons why Tesla stock fell on Thursday
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- AMC Entertainment (AMC) Enters $250M ATM Agreement
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Home Depot (HD) to Acquire SRS Distribution for $18.25B EV
Mizuho Securities Downgrades DepoMed Inc (DEPO) to Neutral
October 4, 2016 6:24 AM EDTMizuho Securities downgraded DepoMed Inc (NASDAQ: DEPO) from Outperform to Neutral with a price target of $27.00 following recent outperformance.
Analyst Irina Koffler commented, "We downgrade to Neutral and reiterate our blended $27 PT as we think that valuation has gotten too rich for new... More
Janney Montgomery Scott Reiterates Buy as Court Rules in Favor of Depomed (DEPO)
October 3, 2016 7:55 AM EDTJanney Montgomery Scott reiterated a Buy rating on DepoMed Inc (NASDAQ: DEPO), and raised the price target to $31.00 (from $28.00), following a court ruling in favor of the company. The Court issued an Order in favor of DEPO in its patent litigation against and secures Nucynta through... More